BioSpace News Archive

Drug Development

Verastem Oncology Announces Publication of the Phase 2 DYNAMO Study Results in Indolent Non-Hodgkin Lymphoma in the Journal of Clinical Oncology

Verastem, Inc. announced that the results of the Phase 2 DYNAMO™ study, which evaluated COPIKTRA™ capsules in patients with indolent non-Hodgkin lymphoma who were refractory to both rituximab and chemotherapy or radioimmunotherapy, was published online in the [peer-reviewed] Journal of Clinical Oncology.

February 14, 2019

·

22 min read

Business

Incyte Reports 2018 Fourth Quarter and Year-End Financial Results, Provides 2019 Financial Guidance and Provides Updates on Key Clinical Programs

Incyte Corporation (Nasdaq:INCY) today reports 2018 fourth quarter and year-end financial results, announces 2019 guidance and provides a status update on the Company’s development portfolio.

February 14, 2019

·

26 min read

Business

Atox Bio Announces Appointment of Robert Greif as Chief Commercial Officer

In this newly created position, Robert will be responsible for building the commercial organization and pre-commercial activities for Reltecimod

February 14, 2019

·

4 min read

Business

Zoetis Reports Fourth Quarter and Full Year 2018 Results

For Fourth Quarter 2018, Zoetis Reports Revenue of $1.6 Billion, Growing 7%, and Net Income of $345 Million, or $0.71 per

February 14, 2019

·

34 min read

Policy

Hill’s Pet Food Faces Class Action for Excessive Vitamin D Levels in Dog Food

Schubert Jonckheer & Kolbe LLP announces its filing of a class action lawsuit against Hill’s Pet Nutrition, Inc. for selling dog food containing excessive and dangerous amounts of vitamin D.

February 14, 2019

·

1 min read

Business

DLH Reports First Quarter Fiscal Year 2019 Results

DLH Holdings Corp., a leading provider of innovative healthcare services and solutions to federal agencies, today announced financial results for its fiscal first quarter ended December 31, 2018.

February 14, 2019

·

11 min read

Policy

Amorsa Therapeutics Announces Notice of Allowance for U.S. Patent Covering Deuterated Norketamine and Related Compounds

Amorsa Therapeutics, Inc. announced that its patent application for deuterated norketamine and related NMDA receptor modulators was allowed for issuance as a new patent by the U.S. Patent and Trademark Office.

February 14, 2019

·

3 min read

Genetown

Lua Technologies, A Subsidiary Of Life Biosciences, Rated As The Leading Post-Acute Secure Messaging Solution By KLAS Research

Lua Technologies, a subsidiary of Life Biosciences Inc, has been ranked the highest scoring post-acute secure messaging solution in the 2018 Secure Communication Decision Insights Report from KLAS Research.

February 14, 2019

·

3 min read

Drug Development

Janssen Announces Preliminary Results from Phase 2 GALAHAD Study in Adults with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Pathway Defects (DRD)

The Janssen Pharmaceutical Companies of Johnson & Johnson will present today at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) early results from the ongoing Phase 2 GALAHAD study evaluating niraparib,

February 14, 2019

·

8 min read

Biotech Bay

Phylagen Secures $14M to Bring Transparency to Global Supply Chains through Microbiome Analytics

Phylagen, the San Francisco-based data analytics company building the world’s largest environmental microbiome database, today announced $14 million in Series A financing led by Cultivian Sandbox, Breakout Ventures and Working Capital

February 14, 2019

·

4 min read